Press Releases
April 24, 2023
Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023
April 19, 2023
Panbela Announces Poster Presentation at American Association for Cancer Research
Evaluating the potential of spermine analogue ivospemin (SBP-101) in combination with chemotherapy in ovarian cancer
View/download poster presentation »
April 12, 2023
First Patient Enrolled in JDRF-Funded Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, Led by Indiana University School of Medicine
April 11, 2023
Panbela Regains Worldwide Rights to Develop and Commercialize Flynpovi™ in Patients with Familial Adenomatous Polyposis (FAP)
April 10, 2023
Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Immunology of Diabetes Society Meeting
April 6, 2023
Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Endocrine Society Meeting
April 3, 2023
Panbela Announces New Research Agreement with Johns Hopkins University School of Medicine
March 22, 2023
Panbela Announces Issuance of New Patent in Japan; Patent is for Claims of a Novel Process for the Production of SBP-101
Patent developed in collaboration with Syngene International Ltd.
March 16, 2023
Panbela Provides Business Update and Reports Q4 and FY 2022 Financial Results
March 8, 2023